Genotoxicity and Cytotoxicity of novel 10B carrier ((2R)-4,5,6-trihydroxy-2-(hydroxymethyl)tetrahydro-2H-pyran-3-yl)boronic acid

Objective: Although surgery and chemotherapy have been greatly successful in the treatment of many types of tumors, these treatment modalities have some limitations. In particular, the side effects of conventional radiotherapy warrant the development of new therapy methods, such as Boron Neutron Capture Therapy (BNCT). In the present study, the cytotoxic and genotoxic properties of novel synthesized boron carrier, ((2R)-4,5,6-trihydroxy-2-(hydroxymethyl)tetrahydro-2H-pyran-3-yl)boronic acid (10BDG), and the apoptotic pathways triggered by 10BDG were examined. Material and Methods: As it defined previously, 10BDG was complexed through a low-high pH reaction and was tested using a Fournier Transform InfraRed-Attenuated Total Reflectance (FT-IR/ATR) spectrophotometer. The cytotoxicity of 10BDG was tested through the MTT assay. The detection of caspases 3, 8, and 9 was performed to determine the activated apoptotic pathways by 10BDG. The Poly (ADP-Ribose) Polymerase (PARP) cleavage and DNA damage induced by this compound were tested through western blot and Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assay, respectively. Results: The average LogIC50 and LogLD50 levels of 10BDG over NCI-H209 cell line were to be found 72.1±10 ug/ml and 171.8±25 mg/kg, respectively. Caspase-9 activation, caspase-3 activation, PARP cleavage, and caspase-3-dependent DNA fragmentation were observed. The genotoxicity analysis was performed using the plasmid fragmentation assay, which revealed the absence of fragmentation. Conclusion: Bio-distrubition analysis showed that boron content was elevated to 12.63 from 4.44 ppm in the tumor tissue by the 10BDG injections. In epitome, 10BDG exhibit slight cytotoxic but no genotoxic properties. Based on the antiproliferative properties of 10BDG, in addition to acting as an adjuvant in cancer radiotherapy and chemotherapy, this compound appears to be an alternative boron carrier for BNCT

[1]  Sabahattin Deniz,et al.  Complexion of Boric Acid with 2-Deoxy-D-glucose (DG) as a novel boron carrier for BNCT , 2014 .

[2]  E. Pozzi,et al.  Biodistribution of sodium borocaptate (BSH) for boron neutron capture therapy (BNCT) in an oral cancer model , 2013, Radiation and environmental biophysics.

[3]  G. Jori,et al.  Boron neutron capture therapy and 18F-labelled borophenylalanine positron emission tomography: a critical and clinical overview of the literature. , 2013, Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine.

[4]  Hiroyuki Nakamura,et al.  Towards new boron carriers for boron neutron capture therapy: metallacarboranes bearing cobalt, iron and chromium and their cholesterol conjugates. , 2013, Bioorganic & medicinal chemistry.

[5]  Michael J. González,et al.  The bio-energetic theory of carcinogenesis. , 2012, Medical hypotheses.

[6]  J. Peir,et al.  Potential of using boric acid as a boron drug for boron neutron capture therapy for osteosarcoma. , 2011, Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine.

[7]  J. Hopewell,et al.  The radiobiological principles of boron neutron capture therapy: a critical review. , 2011, Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine.

[8]  J. Peir,et al.  BNCT for locally recurrent head and neck cancer: preliminary clinical experience from a phase I/II trial at Tsing Hua Open-Pool Reactor. , 2011, Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine.

[9]  T. Gorlia,et al.  Boron neutron capture therapy for newly diagnosed glioblastoma multiforme: an assessment of clinical potential. , 2011, Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine.

[10]  S. Miyatake,et al.  Boron neutron capture therapy for clear cell sarcoma (CCS): biodistribution study of p-borono-L-phenylalanine in CCS-bearing animal models. , 2011, Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine.

[11]  S. Miyatake,et al.  Phase II clinical study of boron neutron capture therapy combined with X-ray radiotherapy/temozolomide in patients with newly diagnosed glioblastoma multiforme--study design and current status report. , 2011, Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine.

[12]  Petre Rotaru,et al.  Calcium Fructoborate—Potential Anti-inflammatory Agent , 2011, Biological Trace Element Research.

[13]  T. Gorlia,et al.  Boron neutron capture therapy for newly diagnosed glioblastoma multiforme: an assessment of clinical potential. , 2010, The British journal of radiology.

[14]  B. Dwarakanath.  Cytotoxicity, radiosensitization, and chemosensitization of tumor cells by 2-deoxy-D-glucose in vitro. , 2009, Journal of cancer research and therapeutics.

[15]  Lisa M Miller,et al.  Assessment of the chemical changes induced in human melanoma cells by boric acid treatment using infrared imaging. , 2009, The Analyst.

[16]  A. Boddy,et al.  A cancer research UK pharmacokinetic study of BPA-mannitol in patients with high grade glioma to optimise uptake parameters for clinical trials of BNCT. , 2009, Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine.

[17]  Kimberly Henderson,et al.  Receptor Activated Ca2+ Release Is Inhibited by Boric Acid in Prostate Cancer Cells , 2009, PloS one.

[18]  S. Capuani,et al.  10B-editing 1H-detection and 19F MRI strategies to optimize boron neutron capture therapy. , 2008, Magnetic resonance imaging.

[19]  M. Vicente,et al.  Recent Progress in the Syntheses and Biological Evaluation of Boronated Porphyrins for Boron Neutron‐Capture Therapy , 2006 .

[20]  M. Vicente,et al.  Recent progress in the syntheses and biological evaluation of boronated porphyrins for boron neutron-capture therapy. , 2006, Anti-cancer agents in medicinal chemistry.

[21]  C. Eckhert,et al.  Cellular changes in boric acid-treated DU-145 prostate cancer cells , 2006, British Journal of Cancer.

[22]  Zuo-Feng Zhang,et al.  Dietary boron intake and prostate cancer risk. , 2004, Oncology reports.

[23]  L. Marks,et al.  Normal-tissue toxicities of thoracic radiation therapy: esophagus, lung, and spinal cord as organs at risk. , 2004, Hematology/oncology clinics of North America.

[24]  R. Maronpot,et al.  Boron Supplementation Inhibits the Growth and Local Expression of IGF-1 in Human Prostate Adenocarcinoma (LNCaP) Tumors in Nude Mice , 2004, Toxicologic pathology.

[25]  A. Shtil,et al.  Carboranylporphyrins for boron neutron capture therapy of cancer. , 2003, Current medicinal chemistry. Anti-cancer agents.

[26]  S. Savolainen,et al.  Study of the relative dose-response of BANG-3 polymer gel dosimeters in epithermal neutron irradiation. , 2003, Physics in medicine and biology.

[27]  A. Ferketich,et al.  Pharmacokinetics of sodium borocaptate: a critical assessment of dosing paradigms for boron neutron capture therapy , 2003, Journal of Neuro-Oncology.

[28]  E. Kreimann,et al.  Biodistribution of a carborane-containing porphyrin as a targeting agent for Boron Neutron Capture Therapy of oral cancer in the hamster cheek pouch. , 2003, Archives of oral biology.

[29]  S. Kulp,et al.  The effects of gossypol on the invasiveness of MAT-LyLu cells and MAT-LyLu cells from the metastasized lungs of MAT-LyLu-bearing Copenhagen rats. , 2000, Anticancer research.

[30]  J. Harper,et al.  Anticancer drug targets: cell cycle and checkpoint control. , 1999, The Journal of clinical investigation.

[31]  A. Soloway,et al.  Boron neutron capture therapy for cancer. Realities and prospects , 1992, Cancer.

[32]  R. Barth,et al.  Boron neutron capture therapy of cancer. , 1990, Cancer research.

[33]  M. Mendelsohn,et al.  Neutron capture therapy with boron in the treatment of glioblastoma multiforme. , 1954, The American journal of roentgenology, radium therapy, and nuclear medicine.

[34]  G. Krystal,et al.  Clinical Cancer esearch cer Therapy : Preclinical inomycin D Decreases Mcl-1 Expression and Acts ergistically with ABT-737 against Small Cell R g Cancer Cell Lines , 2010 .

[35]  K. Henderson,et al.  Receptor activated Ca(2+) release is inhibited by boric acid in prostate cancer cells. , 2009 .

[36]  J. King,et al.  Determining human dietary requirements for boron , 2007, Biological Trace Element Research.

[37]  A. Scovassi,et al.  Changes in extranucleolar transcription during actinomycin D-induced apoptosis. , 2005, Histology and histopathology.

[38]  A. Paetau,et al.  Boron Neutron Capture Therapy of Brain Tumors: Clinical Trials at the Finnish Facility Using Boronophenylalanine , 2004, Journal of Neuro-Oncology.

[39]  R. Müller,et al.  Synthesis and biological evaluation of folate receptor-targeted boronated PAMAM dendrimers as potential agents for neutron capture therapy. , 2003, Bioconjugate chemistry.

[40]  Y. Miyazaki,et al.  Studies on the Complexation of Boric Acid with Polyhydroxyl Compounds , 2002 .

[41]  K. Berg,et al.  Energy metabolism in human melanoma cells under hypoxic and acidic conditions in vitro. , 1997, British Journal of Cancer.

[42]  G. P. Moss,et al.  Glossary of class names of organic compounds and reactivity intermediates based on structure (IUPAC Recommendations 1995) , 1995 .